Skip to main content
ERAS
NASDAQ Life Sciences

Erasca 公布 Q4 净亏损 2910 万美元，基本 EPS 为 -0.1 美元

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$14.74
Mkt Cap
$4.535B
52W Low
$1.01
52W High
$16.405
Market data snapshot near publication time

summarizeSummary

Erasca 公布 Q4 基本 EPS 为 -0.1 美元，净亏损为 2909.2 万美元，营业费用达到 3260.4 万美元。这一财务数据表明，这家临床阶段生物技术公司继续亏损。尽管该公司最近宣布了临床合作和获得其 pan-RAS 分子胶粘剂 ERAS-0015 权利的积极进展，但这些 Q4 财务数据突出了公司在开发阶段典型的现金流失。交易者将监控未来财务报告的盈利进展以及研发投资的影响。

在该公告发布时，ERAS的交易价格为$14.74，交易所为NASDAQ，所属行业为Life Sciences，市值约为$45.4亿。 52周交易区间为$1.01至$16.41。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed ERAS - Latest Insights

ERAS
Apr 28, 2026, 3:58 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Cancer Trial Patient Death Sends Erasca Shares Down 48% After Update
Sentiment: Negative
View Wiseek Article
ERAS
Apr 27, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
9
Erasca Reports Strong Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015 in Solid Tumors
Sentiment: Positive
View Wiseek Article
ERAS
Apr 27, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Erasca Faces Patent Infringement Lawsuit Over Key Drug Candidate ERAS-0015
Sentiment: Negative
View Wiseek Article
ERAS
Apr 21, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Erasca Narrows Data Readout Window for Pan-RAS Molecular Glue ERAS-0015 to Mid-May 2026
Sentiment: Positive
View Wiseek Article
ERAS
Mar 12, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
8
Erasca Secures $242.7M in Public Offering, Extends Runway to H2 2028, and Expands ERAS-0015 Rights
Sentiment: Positive
View Wiseek Article
ERAS
Mar 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Erasca Reports Q4/FY25 Results, Extends Cash Runway, and Reveals Positive ERAS-0015 Clinical Data
Sentiment: Positive
View Wiseek Article
ERAS
Mar 12, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
7
Erasca Reports Q4 Net Loss of $29.1M, Basic EPS at -$0.1
Sentiment: Negative
View Wiseek Article
ERAS
Mar 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Erasca Secures Worldwide Rights for Promising ERAS-0015 Pan-RAS Drug, Expanding Market to China
Sentiment: Positive
View Wiseek Article
ERAS
Mar 05, 2026, 7:01 AM EST
Source: GlobeNewswire
Importance Score:
8
Erasca and Tango Therapeutics Launch Clinical Collaboration for Combination Cancer Therapy
Sentiment: Positive
View Wiseek Article
ERAS
Jan 29, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
Erasca Closes $242.7M Public Offering, Extends Cash Runway into First Half of 2029
Sentiment: Positive
View Wiseek Article